Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TKT | P29401 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14069596 | 0.80 | LMNA (0.45) | LMNAL3MBTL1CYP1A2ALDH1A1PTK2 | |
| SCHEMBL17963963 | 0.80 | GABRP (0.34) | LMNACYP1A2ALDH1A1HTTCYP2C19 | |
| SCHEMBL13304496 | 0.80 | ADORA3 (0.46) | LMNAL3MBTL1CYP1A2ALDH1A1PTK2 | |
| SCHEMBL26970094 | 0.78 | L3MBTL1 (0.42) | LMNAL3MBTL1CYP1A2PTK2POLB | |
| SCHEMBL1069160 | 0.78 | L3MBTL1 (0.42) | LMNAL3MBTL1CYP1A2PTK2POLB | |
| SCHEMBL11470783 | 0.78 | PTK2 (0.58) | LMNAL3MBTL1CYP1A2PTK2POLB | |
| SCHEMBL2275255 | 0.78 | MEN1 (0.43) | LMNAL3MBTL1CYP1A2ALDH1A1PTK2 | |
| SCHEMBL15184467 | 0.78 | L3MBTL1 (0.42) | LMNAL3MBTL1CYP1A2PTK2POLB | |
| SCHEMBL10588098 | 0.78 | L3MBTL1 (0.42) | LMNAL3MBTL1CYP1A2ALDH1A1PTK2 | |
| Carbamic Acid SCHEMBL17964085 | 0.77 | GABRP (0.32) | LMNAALDH1A1PKMKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-11 | — | — | US | disclosed |
| CN-111732535-B | Photochemical synthesis method of heteroaryl amine compound | 天津凯莱英制药有限公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-111732535-A | Photochemical synthesis method of heteroaryl amine compound | 天津凯莱英制药有限公司 | 2020-10-02 | — | — | CN | disclosed |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190175567-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-06-13 | — | — | US | disclosed |
| WO-2009012283-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080227779-A1 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2008011080-A2 | BENZO(D) ISOXAZOLE DERIVATIVES AS C-KIT TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH THE OVER PRODUCTION OF HISTAMINE | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| CN-101103007-A | Amide compound | TAKEDA PHARMACEUTICAL (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-4173646-A | Tricyclicdicarboximides | MERCK & CO., INC. (US) | 1979-11-06 | — | — | US | disclosed |
| US-4132799-A | TRANQUILIZERS, ANTICONVULSANTS | MERCK & CO., INC. (US) | 1979-01-02 | — | — | US | disclosed |
| US-4061763-A | TRANQUILIZER, ANTICONVULSANT | MERCK & CO., INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-4006233-A | TRANQUILIZER, ANTICONVULSANT | MERCK & CO., INC. (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | LMNA 2202/4885L3MBTL1 794/4885CYP1A2 4730/4885 |
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | LMNA 3346/4885L3MBTL1 2773/4885CYP1A2 182/4885 |
| US-20080227779-A1 | Heterocyclic compounds and methods of use | KIT, TPSG1, CMA1 | LMNA 1199/4885L3MBTL1 4555/4885CYP1A2 2255/4885 |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | LMNA 2202/4885L3MBTL1 794/4885CYP1A2 4730/4885 |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, MAP3K13, MAP3K8 | LMNA 2202/4885L3MBTL1 794/4885CYP1A2 4730/4885 |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | LMNA 2202/4885L3MBTL1 794/4885CYP1A2 4730/4885 |
| US-20190175567-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | LMNA 2202/4885L3MBTL1 794/4885CYP1A2 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.